These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25667198)

  • 1. Risk of fracture and the concomitant use of bisphosphonates with osteoporosis-inducing medications.
    Nyandege AN; Slattum PW; Harpe SE
    Ann Pharmacother; 2015 Apr; 49(4):437-47. PubMed ID: 25667198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
    Chen L; Wang G; Zheng F; Zhao H; Li H
    Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.
    de Vries F; Cooper AL; Cockle SM; van Staa TP; Cooper C
    Osteoporos Int; 2009 Dec; 20(12):1989-98. PubMed ID: 19333676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk for atypical fractures associated with bisphosphonate use.
    Lee S; Yin RV; Hirpara H; Lee NC; Lee A; Llanos S; Phung OJ
    Fam Pract; 2015 Jun; 32(3):276-81. PubMed ID: 25846215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for the prevention and treatment of osteoporosis.
    Maraka S; Kennel KA
    BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
    Beard MK
    Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate therapy for secondary osteoporosis: adult perspective.
    Reid IR
    Horm Res Paediatr; 2011; 76 Suppl 1():28-32. PubMed ID: 21778745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
    McClung M; Harris ST; Miller PD; Bauer DC; Davison KS; Dian L; Hanley DA; Kendler DL; Yuen CK; Lewiecki EM
    Am J Med; 2013 Jan; 126(1):13-20. PubMed ID: 23177553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
    Tanaka I
    Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
    Blair MM; Carson DS; Barrington R
    J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis management in patients with breast cancer: EMAS position statement.
    Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
    Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.
    Lim JS; Jin SH; Kim SB; Lee JI
    J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the optimal duration of bisphosphonate therapy?
    Ott SM
    Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
    Papapoulos SE; Schimmer RC
    Postgrad Med J; 2008 Jun; 84(992):307-12. PubMed ID: 18644921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.
    van den Boogaard CH; Breekveldt-Postma NS; Borggreve SE; Goettsch WG; Herings RM
    Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.